Belite Bio announced earlier today the approval from the National Medical Products Administration to initiate the Phase 3 clinical trial of Tinlarebant for geographic atrophy, or the PHOENIX study, in China. The PHOENIX study is a Phase 3, multicenter, double-masked, placebo-controlled, randomized, fixed-dose clinical study designed to evaluate the efficacy and safety of tinlarebant in patients with GA associated with dry age-related macular degeneration. To date, the company has commenced the PHOENIX study in the U.S., Taiwan, Australia, UK, and Switzerland.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLTE:
- Belite Bio initiated with bullish view at Maxim
- Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
- Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
- Belite Bio reports Q3 EPS (40c), consensus (32c)
- Is BLTE a Buy, Before Earnings?
